Publication Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

New Frontiers in Antiangiogenic Therapy: Recent Data on Malignant Gliomas and Metastatic Renal Cell Carcinoma
Angiogenesis in Oncology Vol. 3, No. 1

1 AMA PRA Category 1 Credit(s)™
Release Date: July 18, 2009
Expiration Date: July 18, 2010

Publication Overview

Authors

Jeremy N. Rich, MD; Roberto Pili, MD; Sith Sathornsumetee, MD

Overview and Purpose

Tumor angiogenesis, which is mediated primarily by the vascular endothelial growth factor (VEGF) pathway, plays a key role in solid tumor development. Antiangiogenic approaches have demonstrated benefit in multiple tumor types, including colorectal cancer, non–small-cell lung cancer, breast cancer, and renal cell carcinoma (RCC). Malignant gliomas, which include anaplastic gliomas and glioblastoma multiforme (GBM), are the most common primary brain tumors in adults. Standard treatment of GBM includes surgery followed by an oral alkylating agent both concurrently with radiation therapy and subsequently as adjuvant therapy. Because malignant gliomas are highly angiogenic, antiangiogenic agents have been under intense investigation in these tumors. Recently, an anti-VEGF monoclonal antibody (MoAb) demonstrated encouraging activity as monotherapy and in combination with a topoisomerase I inhibitor in patients with recurrent malignant gliomas. The anti-VEGF MoAb is also being examined as part of the initial treatment regimen for newly diagnosed GBM. Novel agents targeting VEGF and tyrosine kinase inhibitors (TKIs) targeting VEGF receptors (VEGFRs) are being actively studied in both newly diagnosed and recurrent malignant gliomas.

The incorporation of agents targeting angiogenesis, including multitargeted TKIs and mammalian target of rapamycin inhibitors, into therapy for advanced RCC has dramatically improved patient outcomes. Additional antiangiogenic agents, such as more selective TKIs, a MoAb to VEGF, and a VEGFR fusion protein, are undergoing evaluation for the treatment of advanced RCC and could further expand the therapeutic armamentarium. Potential therapeutic strategies that incorporate these agents and other novel approaches to targeting angiogenic signaling are being explored in an effort to prevent or overcome resistance to current therapies for RCC.

The purpose of this activity is to update physicians on the latest developments in antiangiogenic therapies for malignant gliomas and metastatic RCC.

Target Audience

This educational activity is intended for medical oncologists involved in the care of patients with solid tumors. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

Learning Objectives

Upon completion of this educational activity, you should be able to:

  • Discuss clinical data on the use of antiangiogenic agents in the treatment of recurrent malignant gliomas
  • Apply current algorithms for the treatment of RCC, including optimization of antiangiogenic therapies and incorporation of the latest data on the treatment of newly diagnosed disease
  • Evaluate strategies to overcome resistance to antiangiogenic agents in advanced/metastatic RCC

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. Study the educational activity.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

The tests and evaluation must be completed by July 18, 2010, in order for you to receive your certificate.

Complete the test(s) and evaluation by July 18, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy
 It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

Sith Sathornsumetee, MD
No relevant relationships to disclose

Jeremy N. Rich, MD
No relevant relationships to disclose

Roberto Pili, MD
Research Funding – Pfizer Inc.
Paid Consultant – Wyeth Pharmaceuticals

PER Editorial Staff
No relevant relationships to disclose

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Commercial Support
An educational grant for this activity was provided by Genentech BioOncology.

Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users

Compatible Web browsers include:

Additional software requirements include:

Banner Illustration
Illustrator: Erin Moore

Disclaimer
The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Angiogenesis in Oncology
Physicians’ Education Resource
3500 Maple Ave. Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

Download a Print Version of this Publication*

*Print format is for reference only

Educational Grants

An educational grant for this activity was provided by:


  1. Genentech BioOncology